Aldo-keto reductase family 1 member B1 (AKR1B1) is upregulated in gefitinib-, erlotinib-, and osimertinib-resistant lung cancer cells and accelerates the de novo synthesis of glutathione by promoting the cystine transporter solute carrier family 7 member 11 (SLC7A11) expression, thereby reducing treatment-induced stress, such as ROS accumulation, ultimately leading to resistance [93]. Here, AKR1B1 is linked to lung carcinoma.